Lamotrigine (LTG) is a level 1 treatment option for bipolar disorder, as both treatment and prophylaxis of depressive symptoms. It is generally safe and well tolerated, with the rare but serious side effect of Stevens-Johnsons syndrome. This occurs when dose titration is done too fast; hence, a titration phase of 5-6 weeks is recommended.
| BACKG ROU N D
Lamotrigine (LTG) is a level 1 treatment option for bipolar disorder, as both treatment and prophylaxis of depressive symptoms. It is generally safe and well tolerated, with the rare but serious side effect of Stevens-Johnsons syndrome. This occurs when dose titration is done too fast; hence, a titration phase of 5-6 weeks is recommended.
Since valproic acid is no longer recommended as a first-line mood stabilizer in fertile women, LTG is often used in these patients. For birth control, these women often use combined oral anticonceptives (COC) containing ethinyl estradiol and progestins. However, estrogens interact with LTG and potentially lower the plasma concentration up to 60%. 1 Estrogen-induced glucuronidation is responsible for the drop in lamotrigine levels during active COC use. This drug interaction is well documented and is also seen with other ethinyl estradiol containing anticonceptives (eg, vaginal ring), hormonal replacement therapy, and during pregnancy. 1, 2 For use as an anticonvulsant in epilepsy, guidelines recommend the use of a different anticonceptive strategy or to skip the pill-free week. Often, women do not prefer to continuously skip the pill-free week, since this can lead to more breakthrough bleeding (spotting).
When used as a mood stabilizer, it is unclear what effect a pillfree week (and thus variable LTG-concentrations) may have on mood symptoms. Some evidence exists for a plasma concentration-response association, with a therapeutic range between 1-6 µg/mL. 3 The evidence for a clinically relevant therapeutic window is sparse, and therefore, therapeutic drug monitoring is not recommended.
However, in theory, patients have a higher LTG blood level during the pill-free week, which could improve mood or induce more side effects/toxicity, which was reported in a case-report series. 4 On starting with a new COC strip, lowering of the plasma concentration might induce depressive symptoms. Although no randomized controlled trials have been done to confirm or reject these hypotheses, our clinical experience is that Dutch pharmacies may advise bipolar patients to skip the pill-free week.
We present two euthymic patients who completed daily mood monitoring (LifeChart method). No other medication adjustments were made in this period. Plasma concentrations were evaluated three times. The first test was done in the last week of the COC strip.
The second test was done on day 6 or 7 of the pill-free week, since the LTG-concentration increases daily with a peak level on day 6 or 7.
The third test was done in the first week of the COC strip.
| C A S E 1
A 31-year-old consultant was treated for bipolar I disorder at our a combined ethinylestradiol/levonorgestrel (30 μg/150 μg) pill.
Soon after starting lamotrigine, she contacted us for consultation.
The pharmacy had advised her to skip her pill-free week, as this could influence the efficacy of her lamotrigine. With consent of the patient, we decided to do therapeutic drug monitoring after reaching a stabilizing dose of lamotrigine 200 mg once a day, while she kept a daily record of her mood for a month.
| C A S E 2
A 35-year-old designer was recently referred to our outpatient clinic for continuing treatment for her bipolar II disorder. She recently immigrated to the Netherlands, and was already treated successfully with a combination of quetiapine 200 mg once a day, lamotrigine 200 mg twice a day, and fluoxetine 30 mg once a day. The age of onset of her first mood symptoms was at the age of 19, with mainly depressive and anxiety symptoms. Her family history mentions no bipolar disorders, only anxiety disorders (mother). She was admitted once for 3 days, due to severe anxiety and insomnia, when she was 20 years old. When referred to our clinic, she was euthymic for more than a year. She was socially functioning well, recently started an ambitious job and lived with her husband, with whom she had a long and healthy relationship. She used an ethinylestradiol/levonorgestrel (30 μg/150 μg) combination for years, but was not aware of the interaction with lamotrigine. When discussing her mood during her pill-free week, she did not recognize a pattern of mood instability linked to this week. We decided to continue her pill-free week, keep a daily life chart and start therapeutic drug monitoring for a month.
| DISCUSSION
In both patients, a strong variability was shown in the lamotrigine concentrations, probably due to interaction with their COC. The 
Learning points
• Lamotrigine plasma concentrations are potentially lowered up to 60% due to interaction with combined oral anticonceptives containing ethinyl estradiol.
• Our clinical experience is that this variability does not influence mood stability or side effects. A pill-free week may be safe when treating stable bipolar disorder, but there is no evidence for this claim.
• A pill-free week during dose escalation may hypothetically lead to a rapid increase of lamotrigine plasma concentration and thus the risk to induce rare but serious side effects.
LTG-concentrations increased with 52% and 44%, respectively.
There was no effect on mood ( Figure 1 ) and no new side effects 
